What's hot
View all perspectives
What's Hot
Rheumatoid Arthritis Comorbidities
Dr. Jonathan Kay reviews rheumatoid arthritis studies presented on day at EULAR 2022. Specifically, he discusses abstracts OP0132, OP0135 and OP0138.
Watch video →
Increasing Secukinumab Dose in Ankylosing Spondylitis Nonresponders
Dr. Peter Nash discusses abstract OP0023 from EULAR 2022.
Watch video →
DMARDS, Prednisone, Pregnancy, OH MY!
Dr. Kathryn Dao discusses abstracts POS1405, POS0696 and OP0130 presented at the EULAR 2022 meeting. Watch more videos from EULAR 2022 here: https://rheumnow.com/videos.
Watch video →
Breathing New Insight into RA Interstitial Lung Disease
Dr. Jonathan Kay reviews EULAR 2022 abstracts OP0132, OP0306, and OP0307.
Watch video →
EULAR 2022 - Day 4 Faculty Panel Recap
Dr. David Liew and Dr. Jack Cush discuss day 4 of EULAR 2022. LB0001, LB0002, LB0004, and LB0006.
Watch video →
Getting to the Heart of JAK Inhibitors
Dr. Jonathan Kay reviews rheumatoid arthritis sessions and abstracts from day 3 at EULAR 2022. Abstracts reviewed: OP0266; OP0258; and OP0269.
Watch video →
EULAR 2022 - Day 3 Faculty Panel Recap
Drs. Jack Cush, Janet Pope, Aurelie Najm and Yuz Yusof discuss highlights from Day 3 of EULAR 2022.
Watch video →
Deucravacitinib at EULAR 2022
Dr. Peter Nash provides and update on the TYK2 inhibitor, Deucravacitinib with reports on: - Safety of Deucravacitinib https://bit.ly/3NtZQxe - Deucravacitinib in SLE https://bit.ly/3Mh5nG0
Watch video →
Md Yuzaiful Md Yusof Yuz6Yusof
3 years 6 months ago
#LB0006 #EULAR2022 Therapy for relapsing polymyalgia rheumatica. 118/280 recruited re:COVID impact. Phase 3 RCT of Sarilumab+14Wk Steroid taper showed more pts had sustained remission at Wk52 vs PBO+52Wk Steroid Taper(28% vs 10%) even if CRP excluded. PRO improved too! @RheumNow https://t.co/P11iXIAfGn
David Liew drdavidliew
3 years 6 months ago
ECLIPSE UK primary care dataset: 23 million pts @DrMaxYates1
1.
in >55yo, PMR prevalence 2.2%
(10,000 new dx/y)
2.
1/4 take PNL for >4y
(PMR = 18% of all pts on PNL)
3.
mean 3.5 comorbid dx (steroids worsen)
Now tell me we don't need better PMR therapies.
#EULAR2022 @RheumNow
Robert B Chao, MD doctorRBC
3 years 6 months ago
Does treating spondyloarthritis early matter?
Systematic review showed in nr-axSpA tx with biologics may lead to better outcomes compared to established axSpA
axSpA - no difference in response between early vs. established disease
@RheumNow #EULAR2022 ABST#POS0302
Eric Dein ericdeinmd
3 years 6 months ago
#EULAR2022 LB003: W/d MTX w COVID vax
MIVAC 1: hold MTX both vax vs continuing
MIVAC 2: hold after 2nd dose only vs continuing
⭐️MTX hold: improved Ab titers, no diff in MIVAC1/2
⭐️Higher reported flare for holding with both doses (36%) vs just 2nd dose (12%)
@Rheumnow
Aurelie Najm AurelieRheumo
3 years 6 months ago
Sarilumab in PMR
SAPHYR Phase 3 RCT
Underpowered (<50% target recruitment)
-% remission sustained from wk12 to wk 52
28% vs 10% PBO
-Risk of flare reduced HR 0.56
-Improvement of several PROs
No new safety signal
LB0006 @RheumNow #EULAR2022 https://t.co/n7WdQxQaHo
TheDaoIndex KDAO2011
3 years 6 months ago
SAPHYR phase 3 RDBPCT study: #sarilumab vs PCB for relapsing #PMR on pred 7.5+ mg/d. Study met endpoints (whether of or not CRP was included). Time to first flare was longer w/SARI, less steroid use, and also better PROs. AE: #EULAR2022 LB0006 @rheumnow 1/2 https://t.co/lIspLKlveb
Md Yuzaiful Md Yusof Yuz6Yusof
3 years 6 months ago
#LB0002 #EULAR2022 An interesting study design looking at flare rate following withdrawal of drug after WK12. Phase 3 RCT of Baricitinib in paediatric JIA showed 76% met ACR30 at WK12. The Double-blind withdrawal showed less patients on Bari flared vs PBO (17% vs 51%) @RheumNow https://t.co/T0mSDkoHJo
Richard Conway RichardPAConway
3 years 6 months ago
Ramanan et al Baricitinib in JIA. Double blind withdrawal study of prior responders. Earlier flare with PBO vs bari (HR 0.24 [95%CI 0.13,0.45], p<0.001. Less flares with bari vs PBO (17.1% vs 50.6%) p<0.001 @RheumNow #EULAR2022 LB0002 https://t.co/22rp70njRu https://t.co/LtJE9dz0GT
Richard Conway RichardPAConway
3 years 6 months ago
Kohm et al. Efficacy of IL12/23i ustekinumab independent of MTX in PsA. No additive benefit of MTX on joint, skin, QoL, function @RheumNow #EULAR2022 POS1059
TheDaoIndex KDAO2011
3 years 6 months ago
Phase 3 compared Bimekizumab to PCB and Humira; it met all endpoints for PsA; the drug inhibits both IL17F & IL-17A. Safety signal: increase fungal (candidal) infx #EULAR2022 LB0001 @rheumnow https://t.co/MJJwj44YgU
Richard Conway RichardPAConway
3 years 6 months ago
McInnes @IainBMcInnes1 et al. Bimekizumab (IL17A/Fi) in PsA. BE OPTIMAL 852 patient RCT vs PBO vs ADA. Looks same for joints, better for skin than ADA (not stat sig) @RheumNow #EULAR2022 LB0001 https://t.co/oKEHJE3tGn https://t.co/H7nPnbEWUB
Dr. Antoni Chan synovialjoints
3 years 6 months ago
Novel ePROMS use. Use of ePROMS RAPID3/PASS and asking patients if they had a flare had high diagnostic accuracy identifying those not needing DMARD or steroid intensification up and eligible to skip their next outpatient clinic visit. Seppen et al #EULAR2022 @RheumNow POS0381
Dr. Antoni Chan synovialjoints
3 years 6 months ago
Bimekizumab (BKZ) vs PBO at 16 week BE COMPLETE for PsA with inadequate response to TNFi ACR50 44% vs 7%,PASI90 69% vs 7%, ACR20 67% vs 16%, ACR70 27% vs 0.8%, PASI 100 60% vs 5%, MDA 44% vs 6%, no new safety signals #EULAR2022 @RheumNow OP0255 Merola et al https://t.co/riU2sIXGs9
Eric Dein ericdeinmd
3 years 6 months ago
#EULAR2022 LB002
P3 Double-Blind W/d study: Baricitinib for JIA
⭐️All pts start in open label w good benefit (1/2 with ACR70)
⭐️PBO W/d led to 50% flare vs 17% in BARI group, flares earlier
@RheumNow https://t.co/apSSLqu1mp
Md Yuzaiful Md Yusof Yuz6Yusof
3 years 6 months ago
#LB0005 #EULAR2022 Phase 3 RCT of Bimekizumab, dual IL17A and 17F inhibitor in bDMARDs-naive PsA showed significant improvement in ACR50 and PASI90 scores vs Placebo. No major safety signals. Skin response is excellent! @RheumNow https://t.co/yhgB8LGXh6
Poster Hall